• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
What will be the role of molnupiravir in the treatment of COVID-19 infection?莫努匹韦在治疗新冠病毒感染中会起到什么作用？
Drugs Ther Perspect. 2021;37(12):579-580. doi: 10.1007/s40267-021-00879-2. Epub 2021 Nov 5.
2
Molnupiravir, an Oral Antiviral Treatment for COVID-19.莫努匹拉韦，一种用于治疗新冠肺炎的口服抗病毒药物。
medRxiv. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.
3
Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.莫努匹拉韦——一种新型口服抗SARS-CoV-2药物。
Antibiotics (Basel). 2021 Oct 23;10(11):1294. doi: 10.3390/antibiotics10111294.
4
Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect.莫努匹拉韦、法匹拉韦及其他有望用于治疗新冠病毒肺炎的抗病毒药物：关于抗氧化方面的考量
Int J Biochem Mol Biol. 2022 Feb 15;13(1):1-4. eCollection 2022.
5
Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19.工程化核糖基-1-激酶助力简明合成莫努匹拉韦，一种用于治疗新冠肺炎的抗病毒药物。
ACS Cent Sci. 2021 Dec 22;7(12):1980-1985. doi: 10.1021/acscentsci.1c00608. Epub 2021 Oct 29.
6
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.解析莫努匹韦诱导 SARS-CoV-2 突变。
J Biol Chem. 2021 Jul;297(1):100867. doi: 10.1016/j.jbc.2021.100867. Epub 2021 Jun 9.
7
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.二氢乳清酸脱氢酶抑制剂与莫努匹拉韦和N4-羟基胞苷协同作用以抑制新型冠状病毒复制。
iScience. 2022 May 20;25(5):104293. doi: 10.1016/j.isci.2022.104293. Epub 2022 Apr 25.
8
Cost of Goods Analysis Facilitates an Integrated Approach to Identifying Alternative Synthesis Methodologies for Lower Cost Manufacturing of the COVID-19 Antiviral Molnupiravir.商品成本分析有助于采用综合方法来确定用于低成本生产新冠病毒抗病毒药物莫努匹韦的替代合成方法。
Gates Open Res. 2022 Feb 16;6:8. doi: 10.12688/gatesopenres.13509.1. eCollection 2022.
9
Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.从胞苷大规模合成莫努匹拉韦（MK-4482，EIDD-2801）的进展
ACS Omega. 2021 Apr 8;6(15):10396-10402. doi: 10.1021/acsomega.1c00772. eCollection 2021 Apr 20.
10
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.在未住院、未接种疫苗的 COVID-19 成年患者中，莫努匹韦可降低 29 天住院或死亡风险。
Ann Intern Med. 2022 Apr;175(4):JC40. doi: 10.7326/J22-0017. Epub 2022 Apr 5.

引用本文的文献

1
The Value of Ursodeoxycholic Acid and Mesenchymal Stem Cells in the Treatment of Severe COVID-19.熊去氧胆酸和间充质干细胞在治疗重症新型冠状病毒肺炎中的价值
Microorganisms. 2024 Jun 22;12(7):1269. doi: 10.3390/microorganisms12071269.
2
In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.计算机模拟评估天然生物碱对主要蛋白酶和刺突糖蛋白的抑制作用，寻找针对 SARS-CoV-2 的潜在治疗药物。
PLoS One. 2024 Jan 4;19(1):e0294769. doi: 10.1371/journal.pone.0294769. eCollection 2024.
3
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein.吩噻嗪类通过靶向刺突蛋白抑制 SARS-CoV-2 进入。
Viruses. 2023 Jul 31;15(8):1666. doi: 10.3390/v15081666.
4
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.COVID-19 中巨噬细胞活化综合征有吸引力的治疗方法进展。
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
5
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.口服抗病毒药物利托那韦-奈玛特韦和莫努匹韦在多发性骨髓瘤患者中的使用与 COVID-19 重症率低相关：一项单中心前瞻性研究。
Viruses. 2023 Mar 8;15(3):704. doi: 10.3390/v15030704.
6
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19.莫努匹韦治疗在医疗机构 COVID-19 患者中的获益。
Drug Des Devel Ther. 2023 Jan 19;17:87-92. doi: 10.2147/DDDT.S392708. eCollection 2023.
7
Current Treatments for COVID-19: Application of Supercritical Fluids in the Manufacturing of Oral and Pulmonary Formulations.新型冠状病毒肺炎的当前治疗方法：超临界流体在口服和肺部制剂生产中的应用
Pharmaceutics. 2022 Nov 4;14(11):2380. doi: 10.3390/pharmaceutics14112380.
8
Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary after COVID-19 Infection.新冠后综合征：新型冠状病毒感染后肺部治疗的研究进展
Pharmaceutics. 2022 May 26;14(6):1135. doi: 10.3390/pharmaceutics14061135.
9
Efficacy and safety of molnupiravir for COVID-19 patients.莫努匹拉韦对新冠病毒肺炎患者的疗效及安全性
Eur J Intern Med. 2022 Aug;102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.
10
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.妊娠与 COVID-19，关注疫苗和药物治疗。
J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.

What will be the role of molnupiravir in the treatment of COVID-19 infection?

作者信息

Vitiello Antonio, Troiano Valentina, La Porta Raffaele

机构信息

Pharmaceutical Department Usl Umbria 1, Via XIV Settembre-75, Perugia, Italy.

出版信息

Drugs Ther Perspect. 2021;37(12):579-580. doi: 10.1007/s40267-021-00879-2. Epub 2021 Nov 5.

DOI:10.1007/s40267-021-00879-2
PMID:34754175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8570236/
Abstract
摘要